Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neuroendocrine Tumors 6Carcinoid Tumor 5Neoplasms 4Carcinoma 3Vipoma 2Neoplasm Metastasis 2Intestinal Obstruction 2Carcinoma, Islet Cell 2Somatostatinoma 1Recurrence 1Prostatic Neoplasms 1Primary Inoperable Thymoma 1Pleural Effusion 1Peritoneal Neoplasms 1Malignant Carcinoid Syndrome 1Lymphangiomyoma 1Lymphangioleiomyomatosis 1Insulinoma 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Diarrhea 1Chylous Ascites 1Chylothorax 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Ascites 1Adenoma, Islet Cell 1

Interventions

Everolimus 5Topotecan 2Etoposide 2Cisplatin 2Bevacizumab 2veliparib 1pralsetinib 1pertuzumab 1pembrolizumab 1pasireotide 1lenvatinib 1carfilzomib 1cabozantinib 1berzosertib 1Temozolomide 1Sunitinib 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Podophyllotoxin 1Platinum 1Octreotide 1Nivolumab 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Carboplatin 1Capecitabine 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Neuroendocrine × Octreotide × Clear all
NCT01121939 2016-02-05

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

SCRI Development Innovations, LLC

Phase 2 Completed
43 enrolled 9 charts
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡